BALA CYNWYD, Pa.
Feb. 12, 2014
/PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. ("Candence" or the "Company") (Nasdaq –CADX-News) relating to the acquisition by
Click here to learn more about the investigation
, or call: 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Candence shareholders will receive only
in cash for each share of Candence stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Candence for not acting in the Company's shareholders' best interests in connection with the sale process. The transaction may undervalue the Company as it is below the premium paid in comparable transactions and an analyst has set a
per share price target on Candence stock. In addition, the Company has announced OFIRMEV has continued to gain market share and posted year-over-year sales growth of more than 100% in each quarter of 2013.
If you own shares of Candence common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire
at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602,
Bala Cynwyd, PA
19004, by e-mail at
, or by visiting
, calling toll free 877-LEGAL-90. Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.